Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.8735 EUR -0.8%
Market Cap: 592.5m EUR
Have any thoughts about
Pharming Group NV?
Write Note

Pharming Group NV
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pharming Group NV
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Pharming Group NV
AEX:PHARM
Other Long-Term Assets
$38.4m
CAGR 3-Years
27%
CAGR 5-Years
4%
CAGR 10-Years
69%
ProQR Therapeutics NV
NASDAQ:PRQR
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Other Long-Term Assets
$12.3m
CAGR 3-Years
-17%
CAGR 5-Years
34%
CAGR 10-Years
26%
argenx SE
XBRU:ARGX
Other Long-Term Assets
$224.2m
CAGR 3-Years
133%
CAGR 5-Years
263%
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Other Long-Term Assets
$3.5m
CAGR 3-Years
9%
CAGR 5-Years
28%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Other Long-Term Assets
$319k
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pharming Group NV
Glance View

Market Cap
592.7m EUR
Industry
Biotechnology

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

PHARM Intrinsic Value
1.2014 EUR
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Pharming Group NV's Other Long-Term Assets?
Other Long-Term Assets
38.4m USD

Based on the financial report for Sep 30, 2024, Pharming Group NV's Other Long-Term Assets amounts to 38.4m USD.

What is Pharming Group NV's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
69%

Over the last year, the Other Long-Term Assets growth was 36%. The average annual Other Long-Term Assets growth rates for Pharming Group NV have been 27% over the past three years , 4% over the past five years , and 69% over the past ten years .

Back to Top